IDEXX Laboratories, Inc. $IDXX Shares Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.3% during the third quarter, HoldingsChannel reports. The firm owned 206,516 shares of the company’s stock after selling 712 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in IDEXX Laboratories were worth $131,941,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Arkadios Wealth Advisors acquired a new position in IDEXX Laboratories in the 2nd quarter worth $405,000. Orion Porfolio Solutions LLC grew its stake in shares of IDEXX Laboratories by 116.6% during the second quarter. Orion Porfolio Solutions LLC now owns 10,718 shares of the company’s stock valued at $5,749,000 after acquiring an additional 5,770 shares in the last quarter. USA Financial Formulas purchased a new stake in shares of IDEXX Laboratories during the third quarter worth about $2,381,000. Beacon Investment Advisory Services Inc. lifted its stake in shares of IDEXX Laboratories by 15.7% in the third quarter. Beacon Investment Advisory Services Inc. now owns 56,241 shares of the company’s stock worth $35,932,000 after acquiring an additional 7,616 shares in the last quarter. Finally, Plato Investment Management Ltd boosted its holdings in IDEXX Laboratories by 37.1% in the first quarter. Plato Investment Management Ltd now owns 3,087 shares of the company’s stock valued at $1,310,000 after purchasing an additional 835 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on IDXX. Stifel Nicolaus set a $775.00 target price on IDEXX Laboratories in a research report on Monday, November 3rd. BTIG Research increased their price objective on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. UBS Group boosted their target price on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Wall Street Zen upgraded shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Leerink Partners set a $785.00 price target on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $763.50.

IDEXX Laboratories Stock Up 3.6%

NASDAQ:IDXX opened at $706.83 on Wednesday. The company has a current ratio of 1.18, a quick ratio of 0.87 and a debt-to-equity ratio of 0.24. The stock has a 50 day moving average of $701.84 and a 200-day moving average of $640.74. The firm has a market capitalization of $56.44 billion, a PE ratio of 56.05, a price-to-earnings-growth ratio of 3.65 and a beta of 1.67. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, November 3rd. The company reported $3.22 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The firm had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the prior year, the business earned $2.80 EPS. The firm’s revenue was up 13.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the business’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the sale, the executive vice president directly owned 21,149 shares in the company, valued at approximately $14,874,937.66. The trade was a 30.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.98% of the stock is owned by insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.